GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beryl Drugs Ltd (BOM:524606) » Definitions » Current Ratio

Beryl Drugs (BOM:524606) Current Ratio : 1.78 (As of Mar. 2024)


View and export this data going back to 1994. Start your Free Trial

What is Beryl Drugs Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Beryl Drugs's current ratio for the quarter that ended in Mar. 2024 was 1.78.

Beryl Drugs has a current ratio of 1.78. It generally indicates good short-term financial strength.

The historical rank and industry rank for Beryl Drugs's Current Ratio or its related term are showing as below:

BOM:524606' s Current Ratio Range Over the Past 10 Years
Min: 0.96   Med: 1.54   Max: 3
Current: 1.6

During the past 13 years, Beryl Drugs's highest Current Ratio was 3.00. The lowest was 0.96. And the median was 1.54.

BOM:524606's Current Ratio is ranked worse than
56.85% of 1073 companies
in the Drug Manufacturers industry
Industry Median: 1.85 vs BOM:524606: 1.60

Beryl Drugs Current Ratio Historical Data

The historical data trend for Beryl Drugs's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beryl Drugs Current Ratio Chart

Beryl Drugs Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.13 1.24 1.24 1.63 1.78

Beryl Drugs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.63 - 1.60 - 1.78

Competitive Comparison of Beryl Drugs's Current Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Beryl Drugs's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beryl Drugs's Current Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beryl Drugs's Current Ratio distribution charts can be found below:

* The bar in red indicates where Beryl Drugs's Current Ratio falls into.



Beryl Drugs Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Beryl Drugs's Current Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Current Ratio (A: Mar. 2024 )=Total Current Assets (A: Mar. 2024 )/Total Current Liabilities (A: Mar. 2024 )
=102.218/57.554
=1.78

Beryl Drugs's Current Ratio for the quarter that ended in Mar. 2024 is calculated as

Current Ratio (Q: Mar. 2024 )=Total Current Assets (Q: Mar. 2024 )/Total Current Liabilities (Q: Mar. 2024 )
=102.218/57.554
=1.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beryl Drugs  (BOM:524606) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Beryl Drugs Current Ratio Related Terms

Thank you for viewing the detailed overview of Beryl Drugs's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Beryl Drugs (BOM:524606) Business Description

Traded in Other Exchanges
N/A
Address
133, Kanchan Bagh, Ground Floor, Indore, MP, IND, 452001
Beryl Drugs Ltd is a pharmaceutical company principally engaged in the manufacturing and marketing of allopathic pharmaceutical preparations. It also provides contract manufacturing services and veterinary products. It offers manufacturing options for product requirements like small-volume injectables in liquid form, small-volume injectables in dry powder form, eye and ear drops, intravenous fluids in poly pack and glass bottles, and veterinary medicines. The company earns the majority of its revenue from the sale of Bulk Drugs.

Beryl Drugs (BOM:524606) Headlines

No Headlines